Pantop%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520ds

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production. ## Primary Indications * Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD). * Maintenance of healing of erosive esophagitis. * Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome. ## Adult Dosing * **Healing of erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks. * **Maintenance of healing of erosive esophagitis:** 40 mg orally once daily. A dose of 20 mg orally once daily may be used for maintenance in some patients. * **Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome):** Starting dose is typically 40 mg orally or intravenously twice daily. Doses may be increased as needed. Doses up to 240 mg daily have been administered intravenously. ## Pediatric Dosing * **Erosive esophagitis (1 year and older):** * **Intravenous:** 1.0 to 1.5 mg/kg/day, not to exceed 40 mg daily. * **Oral:** 20-40 mg once daily, depending on weight. Doses are typically 20 mg daily for patients weighing 15 kg to <40 kg and 40 mg daily for patients weighing $\ge$40 kg. Duration of treatment is usually 8 weeks. ## Dose Adjustments No dose adjustment is generally required for renal impairment. Dose adjustment is not typically necessary in hepatic impairment, but caution may be warranted with severe impairment. ## Contraindications * Known hypersensitivity to pantoprazole or any component of the formulation. * Concurrent use with rilpivirine-containing products. ## Adverse Effects Common adverse effects include headache, diarrhea, nausea, abdominal pain, flatulence, and dizziness. Long-term use of PPIs may be associated with increased risk of fractures (hip, wrist, spine), Clostridium difficile infection, and vitamin B12 deficiency. ## Key Drug Interactions * **Drugs requiring gastric acid for absorption:** Pantoprazole may decrease absorption of drugs like ketoconazole, itraconazole, and certain HIV medications (e.g., atazanavir, nelfinavir). * **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. * **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Consider potential interactions with drugs metabolized by this enzyme (e.g., clopidogrel, although clinical significance is debated). ## Monitoring * Monitor for signs and symptoms of Clostridium difficile-associated diarrhea. * Consider monitoring vitamin B12 levels with prolonged therapy. * Monitor bone mineral density in patients at risk for osteoporosis. ## Clinical Pearls * Administer oral pantoprazole 30 minutes before a meal. * Intravenous administration should be over at least 15 minutes. * Do not crush or chew delayed-release pantoprazole tablets. * Consider the risks and benefits of long-term PPI use, especially for durations exceeding 1 year. *** *This information is intended for healthcare professionals. Please consult the most current prescribing information and relevant clinical guidelines for complete details and to verify dosages based on patient-specific factors and local protocols.*